Publications Archives - Page 2 of 4 - Alzheon | Preserving Future Memories

4 Dec, 2020

APOE ε4/ε4 homozygotes with early Alzheimer’s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline

alzheon2024-08-09T11:39:48-04:00December 4th, 2020|

17 Aug, 2020

Aducanumab, gantenerumab, BAN2401, and ALZ-801 – the first wave of amyloid targeting drugs for Alzheimer’s disease with potential for near term approval

alzheon2026-07-16T08:05:10-04:00August 17th, 2020|

3 Jan, 2020

The path forward in Alzheimer’s disease therapeutics: Reevaluating the amyloid cascade hypothesis

alzheon2024-06-19T16:32:55-04:00January 3rd, 2020|

2 Dec, 2019

APOE4/4 Subjects with Early Alzheimer’s Disease Show Accelerated Loss of Cortical Thickness and Cognitive Decline Compared to APOE3/3 Subjects

alzheon2026-07-15T10:14:24-04:00December 2nd, 2019|

24 Oct, 2018

APOE4/4 Early to Mild AD Subjects Show High Rates of Hippocampal Atrophy and Cognitive Decline in ADNI-1 and Tramiprosate Datasets

alzheon2019-09-23T12:10:47-04:00October 24th, 2018|

24 Oct, 2018

Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses of Cognitive and Functional Outcomes

alzheon2019-09-23T12:10:47-04:00October 24th, 2018|

3 Aug, 2018

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation In Human Brain

alzheon2024-06-19T16:49:25-04:00August 3rd, 2018|

25 Jul, 2018

Clinical Benefits of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses from the Phase 3 North American Trial

alzheon2019-09-23T12:10:47-04:00July 25th, 2018|

2 Nov, 2017

Sustained Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Alzheimer’s Disease Over 130 Weeks: Results of Phase 3 Extension Study

alzheon2019-09-23T12:10:48-04:00November 2nd, 2017|

23 Oct, 2017

Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease

alzheon2019-09-23T12:10:48-04:00October 23rd, 2017|